Navigating Startup Ecosystems

For years, I thought the unfair advantage in healthtech was obvious: better tech, faster scale, more capital. But after watching dozens of companies rise and fall, I’ve realised something harsh: Those advantages disappear the moment a bigger competitor shows up. The real winners build moats so deep that competitors can’t even see the bottom. Here are the moats I’ve seen work - the ones founders rarely talk about: ▶︎ 1. Data that no one else can touch Flatiron’s AI wasn’t magical. Their oncology datasets, built over a decade of hospital partnerships, were the real moat. Roche paid $1.9B not for the algorithm, but for the data. ▶︎ 2. Turning regulation into a shield AliveCor leaned into the FDA while others avoided it. Every clearance became another wall for competitors to climb. What others saw as a roadblock, they turned into protection. ▶︎ 3. Becoming part of the bloodstream Epic isn’t loved for its UI. But ripping them out feels like open-heart surgery. By embedding deep into hospital workflows, they made themselves almost impossible to replace. ▶︎ 4. Building trust as infrastructure Patients, clinicians, payors - in healthcare, trust is the real currency. Companies that earn it early (privacy, credibility, reliability) build advantages no money can buy. ▶︎ 5. Distribution you can’t churn out of Teladoc didn’t just build telehealth tech. They locked into employer benefit plans. Once inside, churn was close to zero. That’s a distribution moat. ▶︎ 6. Compounding networks Doximity became more valuable with every doctor who joined. Today, 80% of U.S. physicians are on it. That kind of network effect compounds every single day. ▶︎ 7. Surviving regulation without bleeding out Babylon Health raised billions and collapsed in months. In this space, being capital-efficient while navigating regulation isn’t optional — it’s a moat. Notice the pattern? These moats aren’t flashy. They don’t fit neatly in a pitch deck. They’re slow. Painful. Unsexy. But they’re the only advantages that survive when Amazon, Google, or CVS enter your category. So here’s my challenge to healthtech founders: Stop obsessing about speed. Start asking: What asset will compound in value the longer I hold it? What trust can I build that others can’t buy? What constraint am I willing to suffer through that competitors will avoid? Because in healthtech, your unfair advantage often looks like your biggest constraint. What’s the moat you’re building that others can’t copy? #entrepreneurship #startup #funding

There’s a German town you’ve probably never heard of… But it just birthed a $4B AI lab working with Meta, Adobe, and Snap. Welcome to Freiburg, population under 250,000. But quietly becoming Europe’s most overlooked AI hotspot. While most eyes are on Paris or London, Freiburg is doing something different: Not just building fast, but building deep. Not chasing hype, but solving real infrastructure, sustainability, and logistics challenges. Not competing with Silicon Valley, but carving its own ethical, academic, applied-AI identity. Startups here aren’t playing small: -> Black Forest Labs: founded by Stability AI alumni. Now Europe’s answer to OpenAI, powering generative tools for global giants. -> RIIICO: digital twins for factories. -> Sereact: warehouse AI that makes 2-person logistics teams competitive. -> Pluvion & Mondas: building AI for water & energy resilience. -> Prior Labs: redefining how we use tabular data in ML. …all backed by Germany’s quietly growing innovation muscle. And it's not just this city, Germany added 1,500 startups in just the first half of 2025. - VC investment up 45% YoY. - 70% of AI startups collaborate directly with universities. - And the government is putting €12B into the startup ecosystem by 2030. We often talk about “ecosystems.” What’s happening in Freiburg is one of the few actually growing like one, across policy, talent, research, and real-world application. The future of European AI might not come from where you expect. And maybe that’s a good thing.

Which country has the best government–startup relationship in the world? It’s a surprisingly rich question. And one with no single answer. Last month, the UK government appointed Alexandra Depledge, MBE as its first Entrepreneurship Adviser. Her task: tackling the key barriers faced by startups scaling in the UK - no small feat. Other countries have taken different directions. 🇮🇱 Israel: The Yozma model was decades ahead of its time, producing the world’s highest startup density per capita. It combined government risk-sharing with private VC through programs like Yozma, which offered matching funds and favourable buyouts. It helped create Waze, Mobileye and many NASDAQ-listed firms. Much of this was backed by Israel’s Office of the Chief Scientist (now the Israel Innovation Authority), a central force in early-stage tech funding and public-private innovation bridges. 🇪🇪 Estonia: e-Residency turned a small country into a digital powerhouse. Entrepreneurs can set up EU businesses remotely — attracting 120,000+ founders and €67m+ in tax revenue. 🇸🇬 Singapore: The most systematic approach. StartupSG grants and equity (with public/private funds), tax support, and structured business services. It’s the full package. 🇨🇱 Chile: Pioneered the government accelerator model, offering equity-free funding. It’s helped launch 1,800 international startups and build a talent pipeline into South America. 🇨🇦 Canada: Immigration, immigration, immigration. Entrepreneurs securing backing from designated investors can qualify for permanent residency. 🇦🇪 Dubai: Appointed the world’s first Minister of AI and launched innovation-friendly zones like DIFC and Dubai Future Foundation. Policies focus on frontier tech, digital commerce, and global talent. 🇺🇸 USA: Still the gold standard for scale and ambition. While lacking a central startup policy, R&D funding, DARPA, SBIR, and visas like the O-1 create a strong base. Crucially, its risk culture and VC depth do much of the heavy lifting. And then there are the UK and France... one with a new Treasury adviser, the other with unofficial founder back-channels (Xavier Niel and others DMing President Macron). So what works best? Successful models typically: ✔ Share risk (rather than grant cash) ✔ Provide regulatory clarity ✔ Build ecosystems, not just startups ✔ Attract international talent (and support local champions) ✔ Leverage national strengths (digital ID, military tech, tax regimes…) What doesn’t work? Overfunded but underambitious granterpreneurs relying on government rather than markets. Bureaucracy. Pilot programs that never scale. Would love your views. Which countries do this best? And what can the UK learn from them?

What if the best networking strategy had nothing to do with “networking” at all? Back in 2014, I started a group called “Delhi Internet Mafia”. To learn from and share insights with founders based out of Delhi. I would cold email founders to show up for the catchup. Vijay Shekhar Sharma of Paytm showed up for one of them. I remember being blown away by his energy, his ambition and his clarity. We stayed in touch. A few years later, Paytm invested in my startup nearbuy. If it weren’t for that group, we may have never raised money from Paytm. 3 ways to build genuine relationships: 1/ Do not try to impress. Be impressed. People can see through your attempts to impress them. But what people can truly be attracted to is your interest in them. Genuine interest. 2/ Engage meaningfully. If engaging offline, ask questions out of pure curiosity. To truly understand. If engaging online, don’t just comment “Great post!” - add insight or ask smart questions. 3/ Give before you ask. That could be sharing feedback on their work, amplifying their content, or connecting them to someone useful. You can never fail with authenticity and trust.

If we’re being honest, we’ve all already felt this coming — but now the data is definitive. The H1’2024 climate tech funding market has fallen back to 2020 levels. Nothing’s particularly new, though. Since the peak of Q3’21 madness, the climate tech market has been consistently constricting. And to be fair, the market slump isn’t limited just to #climatetech; the broader venture market continues to retrench, be it from sticky inflation, high interest rates, or geo/political chaos. What’s actually novel is that the downtick in funding & deals has finally reached the early stages, and that former darling companies have officially shuttered. Outcomes & key stats: 📉 Seed activity tumbled -30%, echoed by a -25% hit to Series A and B activity, signaling the end of early-stage resilience to the downturn. ⏱ Raising a Series B now takes 2.5x longer than in 2021. 💔 Ten notable climate tech companies filed for bankruptcy in H1’24 including Fisker, Arrival, and Running Tide. The impact to the nascent Carbon sector can’t be overstated, nor is this likely the last shakeup to a former darling startup. 👻 The tourist investors have gone home (-44% count of unique investors), slowing the deployment rate of climate specialist funds. Call it dry powder, slow to fire. Drivers to watch closely: 1️⃣ Graduation rates:  The cohort founded at the start of climate tech’s resurgence in 2018-19 are quickly approaching the Series B cliff. Expect a surge of B-stage urgency to awkwardly coincide with investors taking their sweet time on due diligence (time to raise jumped from 11 to 26 months between rounds!). Meanwhile, growth investment and deals have also dropped precipitously. Late-stage funds are holding on to record levels of dry powder, while holding out for more concrete proof of commercialization and ARR goals. 2️⃣ Fewer, bigger — but better? Despite deal activity rates declining, the deals that did sign & wire were larger and healthier. The average Seed deal size rose 21% verses the year prior. In particular, deep tech startups were able to successfully raise larger rounds. Case in point: Industry sector deals count dropped -41%, while the average Industry deal size jumped +29%. 3️⃣ Sophisticating capital stack:  Despite our “CTVC” name, we’ll be the first to say that the strongest climate tech companies leverage the full climate capital stack -- beyond just venture capital. Many of the most notable deals from the last six months came from companies graduating from equity to project finance and debt in the race to deploy, deploy, deploy. Namely, advanced geo developer Fervo Energy, thermal energy storage provider Antora Energy, and textile-to-textile recycler Syre raised massive rounds for hardware buildouts. Plus, steelmaker H2 Green Steel, lithium extractor Lilac Solutions, and LAES developer Highview Power all raised “FOAK” rounds to support commercial-scale projects. Check out the full Sightline Climate (CTVC) analysis below 👇

Most MedTech startups don’t fail. They just never really scale. Approved. Launched. Selling… a bit. And then they plateau. For years. After working with multiple MedTech startups, I’ve seen a common pattern: The issue isn’t bad technology. It’s underfunded ambition. In MedTech, fundraising isn’t a side task for the CEO. It’s the strategic lever that determines whether the company becomes relevant or remains “interesting.” Here’s where lack of capital quietly kills momentum: 1. Evidence beyond approval The FDA or CE study gets you on the market. It does not get you adoption. Without funding, there’s no: - Sequenced evidence strategy aligned to commercial goals - Comparative data - EU MDR follow-up studies - Payer-relevant endpoints Thin evidence = slow traction. 2. Commercial leadership early enough Hiring a commercial lead 3–6 months before launch is not strategy. It’s damage control. To win, that role should be in place 12+ months before launch with real budget for: - Market development - Positioning - Organizational readiness An early hire without resources is just expensive hope. 3. Marketing that actually educates the market If you don’t fund marketing: - The market doesn’t understand your value - You navigate without real market insight - Sales cycles stretch - Pricing erodes Sales teams cannot build a category alone. 4. Market Access as a capability Global Value Dossiers. Budget Impact Models. Local reimbursement work. Underfund this, and growth stalls 12–24 months post-launch, just when investors expect acceleration. 5. Geographic optionality Focusing on the U.S. is logical. But starving Europe or other regions to “save cash” often destroys long-term value. Preserving options early is affordable. Rebuilding them later is not. The uncomfortable truth: Many MedTech companies never break through because they were never funded to. They linger in permanent scale-up mode. So here’s the real question: Did the CEO raise enough capital to build relevance? Or did investors underestimate what it truly takes to win in MedTech? Because in this industry, capital isn’t about survival. It’s about impact. If you want your company to matter, fund it like it should. ----------------------------------------------------------- I help MedTech companies build real momentum, especially in Europe. Let’s talk. 🔔 Ring my bell to get more posts like this. 🔁 Share if you want to make sure MedTech companies get appropriate funding. 👤 Follow me (Laurent Laffineur) for more insights.

A year has passed since I last visualized the cloud provider landscape, and the changes are striking.  While each provider's strengths remain consistent, several key trends have reshaped the ecosystem: • 𝗧𝗵𝗲 𝗠𝘂𝗹𝘁𝗶-𝗖𝗹𝗼𝘂𝗱 𝗣𝗮𝗿𝗮𝗱𝗶𝗴𝗺:  Organizations are increasingly moving away from single-provider reliance, adopting multi-cloud strategies to optimize spending, avoid vendor lock-in, and leverage best-in-breed services from various platforms. • 𝗚𝗿𝗲𝗲𝗻 𝗖𝗹𝗼𝘂𝗱 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲𝘀:  Sustainability is no longer optional.  Major cloud providers are doubling down on renewable energy and providing tools for customers to monitor and reduce their environmental impact. • 𝗔𝗜/𝗠𝗟 𝗗𝗲𝗺𝗼𝗰𝗿𝗮𝘁𝗶𝘇𝗮𝘁𝗶𝗼𝗻:  The accessibility of artificial intelligence and machine learning has exploded.  Providers are offering increasingly user-friendly tools, empowering businesses of all sizes to harness the power of AI. • 𝗘𝗱𝗴𝗲 𝗖𝗼𝗺𝗽𝘂𝘁𝗶𝗻𝗴'𝘀 𝗥𝗶𝘀𝗲:  Edge computing is transforming industries. Platforms like Azure Arc, AWS Outposts, and Google Anthos are evolving rapidly, enabling innovation in areas like IoT and real-time data processing. • 𝗦𝗲𝗿𝘃𝗲𝗿𝗹𝗲𝘀𝘀 𝗘𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻: Serverless computing continues its ascent, abstracting away infrastructure complexities and allowing developers to focus on code.  Recent advancements have focused on improved tooling and broader functionality. • 𝗧𝗵𝗲 𝗥𝗲𝗽𝗮𝘁𝗿𝗶𝗮𝘁𝗶𝗼𝗻 𝗧𝗿𝗲𝗻𝗱: Interestingly, alongside cloud adoption, some companies are also exploring "reverse cloud," moving certain workloads back on-premise.  This often reflects a focus on cost optimization for specific applications or data governance requirements. The ideal cloud solution remains dependent on individual business requirements.  Regularly evaluating your cloud strategy is essential to ensure it aligns with your evolving needs. What significant shifts have you noticed in the cloud landscape lately? I'm interested in hearing your insights.

Tech is hitting a rare inflection point where the ground shifts faster than leaders can map it.    Arriving just in time for the holidays, Deloitte Tech Trends 2026 (https://deloi.tt/4aEpSfJ) is all about that shift — not someday, not theoretically, but what’s unfolding right now inside the enterprise.    Over the past year, I’ve heard a noticeable change in conversation with tech leaders. The question used to be “if” AI was the right move. Now, it’s about turning experimentation into real impact before they get left behind.   The urgency is real. A technology that once took decades to reach mass adoption now does it in weeks.   Innovation is moving in a flywheel (better models → more apps → more data → more investment → lower costs → even better models) and accelerating faster than any prior tech cycle.    This year’s report zeroes in on five forces reshaping the enterprise:    🟢 Physical AI: Intelligence stepping off screens and into the physical world.  🟢 Agentic AI: Pilots everywhere, yet scarce production, and a focus on why redesigning operations matters more than deploying agents.  🟢 The compute reckoning: Token economics rewriting cloud strategy  as usage skyrockets.  🟢 The great rebuild: Orgs are redesigning around speed, modularity, and human–agent teams.  🟢 AI advantage vs. AI risk: Security racing to defend at machine speed against threats operating with the same intelligence we’re harnessing.    The pattern across all five is more than just an enhancement cycle – it’s a rebuild cycle. And the organizations pulling ahead are the ones willing to rethink the playbook entirely. They’re redesigning instead of automating, prioritizing velocity over perfection, and anchoring every investment to real business outcomes.    So, grab some hot chocolate, a warm blanket, and dive into the trends we’re exploring for 2026 and beyond in Tech Trends 2026. A MASSIVE thank you to all the incredible minds that brought these insights to life: Kelly Raskovich, Jim Rowan, Tim Gaus, Franz Gilbert, Caroline Brown, Nitin Mittal, Parth Patwari, Ed Burns, Nicholas Merizzi, Chris Thomas, Lou DiLorenzo, Anjali Shaikh, Michael Caplan, Erika Maguire, Sunny Aziz, Adnan Amjad, Naresh Persaud, Mark Nicholson, Brett Davis, Simona Spelman, Amit Chaudhary, and Ranjit Bawa. 

Startups are not just dying in Africa. They’re being buried with their brilliance. These are not bad ideas. Not poor teams. Not even weak tech. They’re world-class founders with clear market fits… Failing anyway. And that’s what makes this moment so dangerous. Like many, I love a good success story. But I also follow projects like Startup Graveyard Africa and lately, it’s starting to feel like a memorial wall for some of the continent’s most ambitious ideas. Promising startups. Smart solutions. Strong teams. Still, dead. The reasons are deeper than funding alone. Some blame scared capital. Some blame broken economies. But here’s the hard truth… 👉🏽 We’ve been playing a game that wasn’t designed for us. We’ve imported the Silicon Valley playbook —Blitzscaling. It worked in the U.S. because the system was already built: 1. Power. 2. Broadband. 3. Credit systems. 4. Regulation. They only needed to build the product. But in Africa? We’re often building the market itself. We face what Harvard calls “institutional voids.” No intermediaries. No trust rails. No guaranteed systems to scale on. We’re not blitz-scaling. We’re bridge-building. That’”s why our best founders are choosing a different path. Not quick fixes. Not localized clones. They’re solving coordination problems at the root. They’re building infrastructure that lets other businesses thrive. Take Moove for instance. They didn’t just offer vehicles. They created alternative credit scoring for the unbanked, enabling gig drivers to own assets, earn income, and plug into global platforms like Uber and Bolt. That’s not a product. That’s a system unlock. Across the continent, our most successful startups share two core traits: 1. They enable two-sided network effects, connecting fragmented ecosystems. 2. They tackle infrastructure/institutional problems at their roots, not just surface-level solutions. They’re building new roads where none existed. Not speed-racing on highways someone else paved. So maybe the real question isn’t “why are startups failing?”   It’s: Are we solving the real problem? Or are we just replicating playbooks that never fit our context? If you’re a founder, investor, or ecosystem enabler: What game are you playing? Are you building a business, or building a market? Let’s talk. Drop your thoughts below.

Your HealthTech startup isn’t a tech company. Treating it like one can be fatal. I’ve watched brilliant founders from SaaS, fintech, and AI stumble in healthcare. Not because they lacked skill, but because they assumed healthcare works like every other industry. It doesn’t. Here’s what makes HealthTech a world of its own: 1. You’re selling to institutions, not individuals. Hospitals, insurers, and regulators move carefully, not quickly. Procurement in large systems can take 18+ months, with decisions driven by risk and compliance over hype. Committees replace single decision-makers, and the biggest competitor is often the status quo. 2. Trust is everything. In healthcare, one misstep - clinical, ethical, or regulatory - can destroy credibility overnight. I’ve seen startups lose traction after minor compliance lapses. The rules around AI and digital health evolve constantly, and staying ahead of regulation is now a core competency, not a checkbox. 3. Adoption is the hardest challenge. Clinicians spend roughly 40% of their day on admin tasks. Patients are already overloaded. If your product doesn’t fit seamlessly into existing workflows, it won’t get used... no matter how elegant the tech. True adoption takes empathy, support, and time. 4. Solve a mission-critical problem. In healthcare, survival depends on necessity, not novelty. “Nice-to-have” tools don’t last. Clinical validation through peer-reviewed studies and real-world evidence matters more than hype. Evidence earns trust—and trust drives growth. 5. Investors now expect proof of outcomes. Funding is shifting toward startups that demonstrate measurable clinical impact and sustainable revenue models, especially in high-need areas like maternal health and chronic disease management. Impact now trumps velocity. 6. Partnerships power growth. Strategic collaborations, like those between pharmaceutical companies and AI imaging startups, are shaping healthcare innovation. They help new entrants navigate regulation, gain credibility, and scale responsibly. 7. Play the long game. Healthcare rewards patience, resilience, and humility. Quick hacks and blitz-scaling don’t work here. The founders who listen, learn, and adapt to the system’s realities are the ones who thrive. HealthTech is healthcare. With just enough technology to make it work better, not worse. What would you add?